Use of blood urea nitrogen, creatinine, interleukin-6, granulocyte- macrophage colony stimulating factor in combination to predict the severity and outcome of abdominal sepsis in rats

Inflammation Research

Volumn 61, Issue 8, 2012, Pages 889-897

  Gao, Min ^a   Zhang, Lingli ^a   Liu, Ying ^a   Yang, Mingshi ^b   Wang, Nian ^a   Wang, Kangkai ^a   Ou, Danmin ^a   Liu, Meidong ^a   Chen, Guangwen ^a   Liu, Ke ^a   Xiao, Xianzhong ^a  

^a Central South University   (China)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biomarker; Outcome; Prediction; Prognosis; Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CECAL LIGATION AND PUNCTURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; LIGATION; LOGISTIC REGRESSION ANALYSIS; MALE; MORTALITY; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PUNCTURE; RAT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPSIS; SURVIVAL; SURVIVAL PREDICTION; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

ABDOMEN; ALANINE TRANSAMINASE; ANIMALS; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CHEMOKINE CCL2; CREATINE KINASE; CREATININE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HMGB1 PROTEIN; INTERLEUKIN-6; MALE; PLATELET COUNT; PROGNOSIS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

EID: 84865132025     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0481-3     Document Type: Article

References (25)

1. Alberta C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med. 2003;168:77-84. (Pubitemid 37046636)
2. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ. 2007;335:879-83. (Pubitemid 350069465)
3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-96. (Pubitemid 43810035)
4. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
5. Meisner M. Biomarkers of sepsis: clinically useful? Curr Opin Crit Care. 2005;11:473-80. (Pubitemid 41482704)
6. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-6. (Pubitemid 36444440)
7. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
8. Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008;23:1203-10. (Pubitemid 351767483)
9. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int. 2008;73: 538-46. (Pubitemid 351264114)
10. Sakr Y, Vincent JL, Schuerholz T, Filipescu D, Romain A, Hjelmqvist H, et al. Early-versus late-onset shock in European intensive care units. Shock. 2007;28:636-43. (Pubitemid 350135466)
11. Lin SM, Frevert CW, Kajikawa O, Wurfel MM, Ballman K, Mongovin S, et al. Differential regulation of membrane CD14 expression and endotoxin-tolerance in alveolar macrophages. Am J Respir Cell Mol Biol. 2004;31:162-70. (Pubitemid 39095446)
12. Holly MK, Dear JW, Hu X, Schechter AN, Gladwin MT, Hewitt SM, et al. Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney Int. 2006;70:496-506. (Pubitemid 44141576)
13. Heresi GA. Acute renal failure and sepsis. N Engl J Med 2004; 351:2347-9; author reply 2347-9.
14. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-50. (Pubitemid 36056721)
15. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR. Interleukin 6 is a prognostic indicator of outcome in severe intraabdominal sepsis. Br J Surg. 1994;81:1306-8. (Pubitemid 24275149)
16. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab,)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32:2173-82. (Pubitemid 39491795)
17. Gogos CA, Skoutelis A, Lekkou A, Drosou E, Starakis I, Marangos MN, et al. Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother. 2004;48:2793-8. (Pubitemid 38989138)
18. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine. 2005;29:169-75. (Pubitemid 40126235)
19. Yoon DY, Chu J, Chandler C, Hiyama S, Thompson JE, Hines OJ. Human cytokine levels in nonperforated versus perforated appendicitis: molecular serum markers for extent of disease? Am Surg. 2002;68:1033-7. (Pubitemid 44943155)
20. Remick DG, Bolgos G, Copeland S, Siddiqui J. Role of interleukin- 6 in mortality from and physiologic response to sepsis. Infect Immun. 2005;73:2751-7. (Pubitemid 40570341)
21. Hamilton JA, Anderson GP. GM-CSF Biology. Growth Factors. 2004;22:225-31. (Pubitemid 40123401)
22. Presneill JJ, Waring PM, Layton JE, Maher DW, Cebon J, Harley NS, et al. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality. Crit Care Med. 2000;28:2344-54. (Pubitemid 30604438)
23. Perry SE, Mostafa SM, Wenstone R, McLaughlin PJ. Low plasma granulocyte-macrophage colony stimulating factor is an indicator of poor prognosis in sepsis. Intensive Care Med. 2002; 28:981-4. (Pubitemid 34762238)
24. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med. 2003;29:646-51. (Pubitemid 36523683)
25. Kylanpaa ML, Mentula P, Kemppainen E, Puolakkainen P, Aittomaki S, Silvennoinen O, et al. Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by granulocyte-macrophage colony-stimulating factor and interferon-gamma in vitro. Pancreas. 2005;31:23-7. (Pubitemid 40911498)